ADC Therapeutics falls on confirmatory trial data for lymphoma therapy
Source: SeekingAlpha
2026-06-04 07:02:51 ET
More on ADC Therapeutics
- ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript
- ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
- ADC Therapeutics SA 2026 Q1 - Results - Earnings Call Presentation
- ADC Therapeutics targets $600M-$1B U.S. peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June
- ADC Therapeutics Non-GAAP EPS of -$0.13, revenue of $20.85M beats by $0.86M
Read the full article on Seeking Alpha
For further details see:
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy
ADC Therapeutics SA
NASDAQ: ADCT
ADCT Trading
-18.28% G/L:
$1.14 Last:
4,619,408 Volume:
$1.36 Open:
ADCT Latest News
ADCT Stock Data
$486,217,661
104,923,913
12.45%
40
N/A
Biotechnology & Life Sciences
Healthcare
CH
Epalinges
